[go: up one dir, main page]

AR087672A1 - Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer - Google Patents

Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer

Info

Publication number
AR087672A1
AR087672A1 ARP120103134A ARP120103134A AR087672A1 AR 087672 A1 AR087672 A1 AR 087672A1 AR P120103134 A ARP120103134 A AR P120103134A AR P120103134 A ARP120103134 A AR P120103134A AR 087672 A1 AR087672 A1 AR 087672A1
Authority
AR
Argentina
Prior art keywords
inden
pyrimidin
chloro
amino
methyl
Prior art date
Application number
ARP120103134A
Other languages
English (en)
Inventor
Sue Mcarron Ashley
B Sells Todd
Stirling Matthew
G Stroud Stephen
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR087672A1 publication Critical patent/AR087672A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una entidad química que comprende el compuesto sulfamato de {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-cloro-2-metoxi-2,3-dihidro-1H-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo. Reivindicación 2: La entidad química de la reivindicación 1, donde dicha entidad química es la sal de clorhidrato o un solvato farmacéuticamente aceptable de la misma. Reivindicación 3: La entidad química de la reivindicación 2, donde dicha entidad química es la Forma I sustancialmente cristalina. Reivindicación 13: La entidad química de cualquiera de las reivindicaciones 3 - 7, donde la Forma I se caracteriza por un patrón de difracción de rayos X en polvo (XRPD) que tiene un pico de referencia con un ángulo 2q de 4.5 ± 0.3º, y que tiene picos en ángulos 2q de 3.0º, 4.4º, 5.3º, 8.8º, 9.9º, 10.1º, 10.7º, 11.4º, 12.7º, 15.0º, 15.5º, 16.8º, 17.3º, 17.9º, 18.2º, 19.5º, 20.3º, 21.2º y 21.9º con respecto al pico de referencia.
ARP120103134A 2011-08-24 2012-08-24 Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer AR087672A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
AR087672A1 true AR087672A1 (es) 2014-04-09

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103134A AR087672A1 (es) 2011-08-24 2012-08-24 Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer

Country Status (29)

Country Link
US (3) US8809356B2 (es)
EP (2) EP2748168A4 (es)
JP (1) JP6038150B2 (es)
KR (1) KR20140054288A (es)
CN (1) CN103889988B (es)
AR (1) AR087672A1 (es)
AU (1) AU2012298813B2 (es)
BR (1) BR112014004239A2 (es)
CA (1) CA2846231C (es)
CL (1) CL2014000441A1 (es)
CO (1) CO6900148A2 (es)
CR (1) CR20140128A (es)
DO (1) DOP2014000037A (es)
EA (1) EA031067B1 (es)
EC (1) ECSP14013263A (es)
GE (1) GEP201606522B (es)
HK (1) HK1199252A1 (es)
IL (1) IL231069B (es)
MA (1) MA35439B1 (es)
MX (1) MX2014002015A (es)
MY (1) MY166889A (es)
PE (1) PE20141146A1 (es)
PH (1) PH12014500419A1 (es)
SG (2) SG10201601023UA (es)
TN (1) TN2014000080A1 (es)
TW (1) TWI577667B (es)
UA (1) UA114894C2 (es)
UY (1) UY34292A (es)
WO (1) WO2013028832A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
SG10201601023UA (en) * 2011-08-24 2016-03-30 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
ES2739150T3 (es) 2012-02-17 2020-01-29 Millennium Pharm Inc Inhibidores de pirazolopirimidinilo de la enzima activadora de ubiquitina
CA2880813A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. Indole-substituted pyrrolopyrimidinyl inhibitors of uba6
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CN105492429A (zh) * 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
LT3164130T (lt) 2014-07-01 2019-11-25 Millennium Pharm Inc Heteroarilo junginiai, tinkami panaudoti kaip sumo aktivuojančio fermento inhibitoriai
KR101927375B1 (ko) * 2016-04-20 2018-12-11 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ES2390803T3 (es) 2005-02-04 2012-11-16 Millennium Pharmaceuticals, Inc. Inhibidores de las enzimas activadoras E1
EP1989206B1 (en) * 2006-02-02 2012-07-04 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzyme
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP2049491B1 (en) * 2006-08-08 2010-10-20 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of e1 activating enzymes
RU2562245C2 (ru) 2009-05-14 2015-09-10 Милленниум Фармасьютикалз, Инк. ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА
SG10201601023UA (en) * 2011-08-24 2016-03-30 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
EP2773360B1 (en) * 2011-11-03 2018-02-28 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Also Published As

Publication number Publication date
IL231069A0 (en) 2014-03-31
EP3323414A1 (en) 2018-05-23
US8809356B2 (en) 2014-08-19
TW201313689A (zh) 2013-04-01
WO2013028832A2 (en) 2013-02-28
CL2014000441A1 (es) 2014-09-26
MA35439B1 (fr) 2014-09-01
ECSP14013263A (es) 2014-04-30
EA031067B1 (ru) 2018-11-30
BR112014004239A2 (pt) 2017-03-21
US20130150388A1 (en) 2013-06-13
KR20140054288A (ko) 2014-05-08
US20180290983A1 (en) 2018-10-11
TWI577667B (zh) 2017-04-11
TN2014000080A1 (en) 2015-07-01
CN103889988B (zh) 2018-05-04
SG10201601023UA (en) 2016-03-30
IL231069B (en) 2018-02-28
CN103889988A (zh) 2014-06-25
CA2846231C (en) 2017-06-20
GEP201606522B (en) 2016-08-10
EP2748168A4 (en) 2015-04-22
EA201400249A1 (ru) 2014-05-30
AU2012298813A1 (en) 2013-05-02
WO2013028832A3 (en) 2013-05-02
MY166889A (en) 2018-07-24
UY34292A (es) 2013-04-05
EP2748168A2 (en) 2014-07-02
CO6900148A2 (es) 2014-03-20
AU2012298813B2 (en) 2016-07-28
MX2014002015A (es) 2014-03-27
CA2846231A1 (en) 2013-02-28
US9850214B2 (en) 2017-12-26
SG11201400102WA (en) 2014-03-28
JP6038150B2 (ja) 2016-12-07
UA114894C2 (uk) 2017-08-28
DOP2014000037A (es) 2014-04-15
JP2014524476A (ja) 2014-09-22
CR20140128A (es) 2014-05-15
NZ622220A (en) 2016-04-29
PH12014500419A1 (en) 2020-06-22
PE20141146A1 (es) 2014-09-21
US20150011572A1 (en) 2015-01-08
HK1199252A1 (en) 2015-06-26

Similar Documents

Publication Publication Date Title
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
AR122395A2 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
AR084824A1 (es) Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
BR112017012755A2 (pt) compostos de heteroarila de anel fundido e seu uso como inibidores de trk
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
MX2016006336A (es) Compuestos pirazolopirimidina.
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA201492125A1 (ru) НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2013005833A (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
PE20120907A1 (es) Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
MX2013012588A (es) Inhibidores de cinasa.
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
AR073117A1 (es) Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios.
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
EA201391524A1 (ru) Производные гликозида и их применение
EA201692298A1 (ru) Производные карбоксамидов

Legal Events

Date Code Title Description
FB Suspension of granting procedure